Ayma Therapeutics Completes Acquisition of AIDE Technology Platform, Solidifying Leadership in Red Blood Cell-Based Drug Delivery
Strategic addition of AIDE to Ayma's existing ERYCAPS platform, positions the company as a pioneer in red blood cell-mediated therapeutic and diagnostic delivery
PRINCETON , N.J. — 08 Sept.2026 — Ayma Therapeutics, a precision drug-delivery company, today announced the successful acquisition of the AIDE (Autologous Intracellular Drug Encapsulation) technology platform and its associated Italian operations, from Quince Therapeutics, Inc. (Nasdaq: QNCX).
This transaction unites AIDE, eDSP and ERYCAPS -previously acquired from Phaxiam Therapeutics- as fully-owned, proprietary red blood cell encapsulation platforms under Ayma’s corporate roof, strengthening its position as a leader in red blood cell-mediated therapeutic and diagnostic delivery. This dual-platform approach enables Ayma to advance precision therapies utilizing both centralized and point-of-care red blood cell encapsulation applications.
"This acquisition represents a pivotal step forward placing Ayma at the forefront of red blood cell-mediated delivery," said Ramesh Gopalan, Co-Founder and CEO of Ayma Therapeutics. "Bringing AIDE into Ayma alongside ERYCAPS gives us a broader, more versatile foundation to accelerate meaningful therapies across rare disease, pulmonary medicine, acute care, and lymphatic diagnostics and therapeutics."
The comprehensive asset transfer includes the AIDE and eDSP global intellectual property estate, proprietary manufacturing infrastructure, the operational control of Ayma’s subsidiary in Medolla, Italy, and an extensive portfolio of regulatory, preclinical, and clinical data packages generated through years of eDSP development, providing Ayma with a substantial foundation for future product development and regulatory activities.
About Ayma Therapeutics
Ayma Therapeutics is a biotechnology company redefining precision medicine via its two proprietary red blood cell-based encapsulation platforms, ERYCAPS and AIDE. By leveraging the natural properties of red blood cells in optimizing drug delivery, the company is actively advancing a targeted pipeline addressing unmet or inefficiently met needs in rare disease, pulmonary medicine, acute care, and lymphatic diagnostics and therapeutics. Ayma is headquartered in Princeton, New Jersey.
Latest Advances in Cardiovascular and Respiratory Therapeutics
Ayma Therapeutics Inc, a privately owned IND stage company with primary office in Princeton, NJ has acquired the assets of Phaxiam, France, specifically related to former capabilities of Erytech and their red blood cell (Erycaps) technology. These assets include intellectual property (IP), hardware, software, documentation and other know-how related to encapsulation of drugs into red blood cells, testing, release and delivery to human subjects and patients in the clinic.
Since Ayma's technology is based on delivering a small molecule (Triciribine Phosphate) in red blood cell encapsulated formulation for effective delivery to target tissues involved in disease pathology for various cardiopulmonary indications, this acquisition is anticipated to directly contribute to development, testing, approval and commercialization of AYX-101, Ayma's flagship product.
As a result of this acquisition, Ayma is now poised to advance AYX-101 as a novel therapeutic using Erycaps technology and know-how that has been previously clinically validated after being successfully dosed to normal healthy volunteers (Phase I) and in patients (Phase II and III). This is a testament to strong regulatory record for Erycaps in the US and EU regions allowing Ayma to leverage this precedence and successfully initiate Phase I trial for AYX-101 in 2026.
Furthermore, this acquisition strengthens Ayma's portfolio since the combined IP provides several additional opportunities for AYX-101 in similar and other therapeutic areas either as monotherapy or in combination with approved products for the treatment of cardiopulmonary disorders including ARDS, pulmonary fibrosis and rare diseases with significant unmet needs.